Document is current
Any future updates will be listed below
-
Authors
Munyombwe, T.
Dondo, T. B.
Aktaa, S.
Wilkinson, C.
Hall, M.
Hurdus, B.
Oliver, G.
West, R. M.
Hall, A. S.
Gale, C. P.
-
Funding
Funding for this research was provided by:
British Heart Foundation (PG/19/54/34511)
National Institute for Health Research (NIHR/CS/009/004)
- License Information
-
More Information
Article History
Received: 21 April 2021
Accepted: 16 August 2021
First Online: 28 September 2021
Declarations
:
: Ethics approval EMMACE-3 and EMMACE-4 were given a favourable ethical opinion by the Leeds (West), and West Midlands Research Ethics committees (REC reference: 10/H131374 and 12/WM/0431) are registered on(NCT01808027 and NCT01819103) and were adopted onto the National Institute for Health Research Comprehensive Research Network portfolio (9102). Patients were consented to participate into the EMMACE studies by a trained researcher during their hospital admission.
: Not applicable
: Prof Gale reports grants from Abbot Diabetes, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Bayer, grants from BMS, personal fees from Daiichy Sankyo, and personal fees from Vifor Phamra outside the submitted work. Dr Wilkinson reports a research grant from BMS. The other authors declare that they have no competing interests.
